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Introduction 
Obesity and the associated health concerns have become popular topics in the medical 
community due to the epidemic status they have reached in many developed countries. Obesity 
creates significant economic stress due to medical costs, and also often leads to decreased life 
expectancy and quality of life9. Obesity in humans is known to be linked to health issues 
including insulin resistance, hypertension, and atherosclerosis which lead to serious 
complications, including death9.   
Atherosclerosis is an especially dangerous complication of obesity because it can lead to 
obstruction of the arteries supplying blood to the heart. Diseases of the heart are the leading 
cause of death in the United States, accounting for 25% of all deaths in the year 20074. Of these 
heart disease related deaths, 66% resulted from ischemic (coronary artery) disease and 22% 
resulted from acute myocardial infarction4. Both ischemic heart disease and myocardial 
infarction are possible complications of atherosclerosis5. Because of the significant mortality 
associated with this disease, research relating to atherosclerosis mechanisms as well as possible 
treatments is of utmost importance. 
The development of atherosclerosis occurs in several steps. The first step involves the 
formation of a fatty streak, which occurs when lipoproteins are transported into the arterial walls. 
This process is initially dependent on the difference in concentration of LDL cholesterol inside 
and outside the cell and its interaction with the LDL receptor. Once the lipid is inside, the 
development of plaques depends more on the retention of the lipid in the arterial wall, not the 
rate of transport, regardless of concentration2.  
The next step is oxidation of the lipids within the artery wall. This process occurs in two 
phases; first, LDL is mildly oxidized by monocytes, then LDL is further oxidized by 
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macrophages. One product of this oxidation, lysophosphatidylcholine, attracts monocytes and T-
lymphocytes while simultaneously inducing vascular cell adhesion molecule-1 (VCAM-1) which 
binds to these immune cells on the vascular wall5. Once strong oxidation occurs, LDL receptors 
are impaired and lipids are transported into the cell without regard to concentration in the cell, 
resulting in an abundance of lipids in the cytoplasm. These cells are referred to as foam cells 
because of the foamy consistency the cytoplasm takes on2. 
Once this fatty streak has formed, the lipid core may continue to expand and eventually 
intrude into the lumen of the vessel. As the lipid core grows, proteinases begin to be secreted by 
activated leukocytes, breaking down the extracellular matrix. Additionally, pro-inflammatory 
cytokines including INF-tau can limit synthesis of new collagen. This causes the fibrous cap of 
the vessel wall to weaken, making it susceptible to rupture. If the plaque ruptures, a thrombus 
will form and occlude the artery. This can result in two outcomes: it may completely block the 
vessel, resulting in a clinical event such as myocardial infarction, or if it only partially occludes 
the lumen the thrombus may be repaired by thrombolysis and resorbed. This triggers a wound 
healing response with release of platelet derived growth factor (PDGF) and transforming growth 
factor-β (TGF-β), causing smooth muscle cells to proliferate and collagen to be produced as scar 
tissue. This strengthens the fibrous cap on the vascular wall, but it also causes the blockage to 
intrude further into the lumen. This leads to a more chronic condition such as ischemia5. 
Atherosclerosis is an inflammatory disease that, in the past, was mainly considered a 
degenerative disease which was not preventable2. Treatment mostly focused on prevention 
through reduction of LDL cholesterol, and was not as effective as would be expected – reduction 
of LDL levels typically results in only, at best, a one-third improvement over five years5. This 
may be due in part to the fact that in developed nations, cholesterol levels that are considered 
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average among the population still greatly exceed the normal level expected for humans 
according to levels seen in animals as well as humans in agrarian societies5. Because of these 
limitations of LDL cholesterol reduction, alternative methods to reduce atherosclerosis are 
increasingly being considered. 
Omega-3 Polyunsaturated Fatty Acids (PUFA) are one type of supplement that has 
emerged as a possible prevention method for atherosclerosis. There are several mechanisms by 
which Omega-3 PUFA have been shown to mediate atherosclerosis. One of these is the reduction 
of plasma concentration of triglycerides and VLDL cholesterol. This reduces one of the main 
initial triggers of atherosclerosis. Another mechanism is inhibition of thrombus formation by 
substituting in the place of arachidonic acid on the endothelium. Arachidonic acid derived 
metabolites have a tendency to be more prothrombotic and more vasoconstrictive than the 
metabolites of Omega-3 PUFA. This process mediates the clot formation that can occlude the 
vessel in atherosclerosis and prevents the lumen space from becoming smaller due to 
vasoconstriction. However, this does not cause a drastic reduction in atherosclerosis3. 
Mechanisms that may have more significant anti-atherosclerotic effects are the suppression of 
inflammatory cytokines such as IL-1 and TNF in monocytes, reduction of PGDF production, and 
reduction of adhesion factors responsible for the binding of immune cells such as VCAM-1. 
These cytokine based mechanisms are the main focus of present studies of atherosclerosis 
prevention because they are still not fully understood and they have strong potential as a 
preventative measure for the process of atherosclerosis3. 
Swine are increasingly being seen as a viable model for atherosclerosis in humans due to 
their anatomical similarities, particularly in the cardiovascular system. The coronary vascular 
system is similar to 90% of the human population, which makes development of coronary artery 
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disease in pigs an excellent model for human coronary artery disease8. The metabolism of the pig 
and its development of obesity have also been shown to be similar to humans. Swine are devoid 
of brown fat postnatally and the size of the adipose tissue in swine is adequate for analysis of 
samples through assays; this makes the swine model superior to rodent models used in the past8.   
The purpose of this study is to develop a model of obesity-induced atherosclerosis similar 
to that seen in humans. If successful, this swine model can be used to pursue possible treatments 
for atherosclerosis as well as develop a more detailed understanding of the mechanisms behind 
the gene expression control of progression of the disease. The pilot study will test the efficacy of 
a 16 week trial of high fat diet in inducing atherosclerosis. This diet is expected to cause 
significant increases in body weight, blood triglyceride and cholesterol levels, and development 
of identifiable fatty plaques on the artery walls as shown in past studies of obesity correlated 
conditions6. It would also be expected that inflammation would cause an increase in the stress 
hormone, cortisol, and decreases in cortisol-inactivating Corticosteroid Binding Globulin (CBG) 
resulting in a higher level of free, active cortisol in the bloodstream (Free Cortisol Index)1. The 
first treatment that is being tested is supplementation of this high fat, atherosclerosis-inducing 
diet with Omega-3 PUFA. Supplementation of the high fat diet with Omega-3 PUFA is expected 
to mediate inflammation and the adverse health effects of the diet, including obesity, blood 
triglyceride and cholesterol levels, cortisol and CBG levels and overall development of 
atherosclerosis3. 
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Materials and Methods: 
Pilot study: 
Two miniature swine from Sinclair Bio Resources7 were obtained at the age of 7 months, 
both castrated males. Both were fed a high fat diet consisting of Purina Mills Laboratory Mini-
Pig Breeder Chow (75% of diet) supplemented with Coconut Oil (17.2%), Corn Oil (2.3%), 
Sodium Cholate bile salt (1.5%), and Cholesterol (4.0%). This diet was fed for 16 weeks. 
Measures of body weight and fasting blood samples were taken at baseline and at 4 week 
intervals afterward, and blood samples were analyzed for glucose levels, cholesterol and 
triglyceride content, and cortisol and Corticosteroid Binding Globulin (CBG). Glucose was 
measured at the time each sample was taken using a Glucometer. Cholesterol and triglycerides 
were measured from the blood samples in the University of Tennessee Pathology Laboratory. 
Cortisol was measured by Radioimmunoassay and Corticosteroid Binding Globulin was 
measured by ELISA. Free Cortisol Index was obtained from the Cortisol to CBG ratio. 
At baseline and at 4 week intervals, the pigs were sedated with ketamine (10 mg/kg) and 
midazolam (0.4 mg/kg) intramuscularly and transported to the University of Tennessee Graduate 
School of Medicine where Positron Emission Tomography (PET) and X-ray Computed 
Tomography (CT) scans were taken. IV catheters were placed for anesthetic support as well as 
administration of radiopharmaceutical and vascular contrast agent (1 ml/kg Omnipaque). 
Tracheal intubation was also performed with administration of inhaled isofluorane/oxygen in 
sternal recumbency for 60 minutes during the radiopharmaceutical uptake period and acquisition 
of whole-body PET/CT images. The CT scans were used to find measurements of back fat depth 
and abdominal and pericardial fat volume. 
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At the conclusion of the 16 week study, the pigs were euthanized and a necropsy was 
performed. Samples of liver, pancreas, thymus, spleen, visceral and subcutaneous fat, and artery 
wall were obtained and flash frozen using liquid nitrogen. Sections of arteries were also taken 
and preserved in formalin for future photography and examination. 
Omega-3 PUFA study: 
 Eight miniature swine from Sinclair Bio Resources were obtained at the age of 7 months, 
all castrated males. Four of these swine were fed the same high fat diet as in the pilot study as a 
control group, while four were fed this high fat diet plus a supplement of Grow Mega fish oil. 
One of the control pigs and one of the Omega-3 PUFA supplement pigs were each removed from 
the study due to health concerns. One developed a gastric ulcer while the other developed an 
upper respiratory infection; both were treated for these conditions and switched to a non-high fat 
diet for the remainder of the study period. They were not included in the final data for either 
group. 
 Measures of body weight and fasting blood samples were taken in 4 week intervals as 
described in the pilot study. The PET and CT scans were not repeated for this study. At the 
conclusion of the study, euthanasia and necropsy were performed as in the pilot study. Samples 
of liver, pancreas, lymph node, thymus, spleen, subcutaneous and abdominal fat, and artery were 
obtained and flash frozen using liquid nitrogen. Sections of arteries were also taken and 
preserved in formalin for future photography and examination. 
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Results and Discussion 
Pilot Study 
Figure 1: Body weights of the two minipigs over the course of the 16 week trial.
value indicates a significant difference
consistent linear increase in both pigs. 
revealed significant weight gains
was hypothesized for this high fat diet trial.
Figure 2: Circulating concentrations of plasma cholesterol (left) and triglycerides (right)
stated P-value indicates a significant difference
interest is the pig-to-pig variation, which will need to be 
reason for the peak concentration at 8
require further investigation. The increases 
hypothesized for this high fat diet trial.
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 between start and end of trial. Body weight showed a 
A pre-planned comparison between start- 
 in these mature pigs. These results are compatible with what 
 
 between start and end of trial. Of particular 
accounted for in future studies
-12 weeks followed by a decrease is also unknown and will 
from baseline are compatible with what was 
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Figure 3:  Plasma concentrations of cortisol (top left), CBG (top right) and values for the Free 
Cortisol Index (bottom). No significan
Cortisol Index. There was an observed increase in CBG from baseline to final measurement, but 
because there is no correlation of the
drawn from this difference. It was hypothesized that increased inflammation would cause 
cortisol to increase while CBG would decrease. This correlation was not proven in this trial.
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Figure 4: Circulating concentration of blood glucose after overnight fasting.
or difference was observed in fasting blood glucose values
conclusion of the experiment. This result was no
focus of the study, development of atherosclerosis. It was hypothesized that the high fat diet 
would likely induce a diabetic or 
fasting blood glucose. This condition was not obs
more obesity related health conditions such as this could occur over a longer time period, but 
further investigation is needed in this area.
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 No significant trend 
 from the baseline values to the 
t as hypothesized, but did not affect the main 
pre-diabetic insulin resistant condition, causing
erved in this 16 week trial. It is possible that 
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Figure 5: Representative CT images showing increased backfat 
pericardial fat volume (pink, A,C,D and F) and visceral fat volume (B,C,E and F) from the 
beginning (A-C) to the end (D-F) of the trial.
hypothesized for this high fat diet trial.
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depth (white arrow, A and D), 
 These increases are compatible with what was 
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Figure 6: Measures of back fat depth, abdominal fat volume, and pericardial fat volume as 
obtained by CT scans. A significant increase was seen in all of these values, though there was 
wide pig-to-pig variation in pericardial fat volume
compatible with what was hypothesized for this high fat diet trial. Further investigation is needed 
to determine the reason for the variation in the location of fat depots between pigs.
Table 1: Rates of accumulation of visceral (abdominal) and pericardial fat depots over the 
course of the trial.  Accumulation occurred in a linear fashion.
what was hypothesized for this high fat diet trial.
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Figure 7: Representative cross sections of 
coronary artery (right). Near-total occlusion of the arteries occurred over the span of the 16 week 
trial. This is a direct observation of the induction of atherosclerosis 
hypothesized, atherosclerotic plaques were created in this model.
 
Figure 8: Representative cross section of  caudal aorta
representative longitudinal and cross sections of  thoracic aorta
the caudal artery occurred over the span of the 16 week trial.
induction of atherosclerosis in this model. As hypothesized, atherosclerotic plaques were created 
in this model. Additionally, symptoms of peripheral artery disease were observed in these pigs, 
showing evidence that these plaques caused ischemia of the caudal artery and possibly other 
portions of the peripheral vascular system.
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caudal aorta at the level of renal artery (left
in this model.
 
 
 immediately distal to kidney (left
 (right). Near-total occlusion of 
 This is a direct observation of the 
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Omega-3 PUFA Study 
 
Figure 9: Average values of body weight for
groups. Over the course of the trial, the PUFA supplemented group had a lower body weight for 
the most part. The PUFA group started out at a slightly higher average weight than the 
group, so this trend is not seen until week 8 of the trial.
to gain more weight over the trial period than PUFA pigs did (21.2 ± 2.6 
0.09).  These results are all compatible with the hypothesi
weight gain than the high fat diet without supplementation.
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 high fat diet Control and PUFA-supplemented 
 In terms of total gain, control pigs tended 
vs. 15.2 ± 0.9; p = 
s that the PUFA diet would show less 
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Figure 10: Plasma concentrations of cholesterol (top) and triglycerides (bottom). 
these values is similar to that seen in the pilot study
subsequent decrease. Interestingly, the PUFA group had a higher concentration of both 
cholesterol and triglycerides at the peak point, followed by a significant drop, putting the
values lower than or equal to the 
investigation is needed in this area. The overall increase in cholesterol and triglycerides is lower 
in the PUFA group compared to the control, as hypothesized.
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control group. The reason for this is unknown and further 
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Figure 11: Plasma concentrations of cortisol (top left), CBG (top right) and values for the Free 
Cortisol Index (bottom). The results of these
pattern. Due to an expected decrease in inflammation with PUFA supplementation, the 
concentration of cortisol would theoretically decrease while CBG would increase compared to 
the control. In this trial, the opposite seems to have occurred, and the overall free cortisol 
increased in the PUFA group. The reason for this is unknown. Testing for
anti-inflammatory cytokines present in the blood, currently in progress, may explain this 
discrepancy. 
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Figure 12: Circulating concentration of blood glucose after overnight fasting. Similar to the pilot 
study, no statistically significant change in blood glucose was seen between the baseline and 
final readings. The 16 week trial does not induce insulin resistance as was hypothesized, and 
there is no significant difference between the PUFA and control groups.
 
 
 
Statistical analysis 
Variables were analyzed in SAS (SAS Institute, Cary, NC, USA) with use of the mixed model 
ANOVA. All data were analyzed with repeated measures. Least squares means were compared 
with Fisher’s protected LSD. Significance was set at P 
were also noted in a priori comparisons of treatment effects at each time point. All figures depict 
raw means and SEs. 
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≤ 0.05, but trends when 0.10 
17 
≥ P ≥ 0.05 
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Discussion 
 This trial was successful in creating a model of obesity and atherosclerosis in swine that 
is similar to that seen in humans, including clinical signs of ischemia. Both the pilot study and 
the control group of the Omega-3 PUFA trial showed significant increases in body weight and 
development of atherosclerosis. The Omega-3 supplementation trial had mixed results, with 
body weight and cholesterol and triglyceride concentrations being decreased as expected, while 
free cortisol showed the opposite result compared to what was hypothesized. Testing of gene 
expression based pro-inflammatory and anti-inflammatory cytokines is currently in progress, and 
may show more clearly what is occurring in terms of inflammation with Omega-3 PUFA 
supplementation. Additionally, arterial samples from the Omega-PUFA study are currently being 
analyzed as in the pilot study for plaque development. This may show more of the positive 
effects of PUFA supplementation. The model for atherosclerosis that has been developed in this 
experiment can be used for future treatment models as well as further investigation of the 
molecular mechanisms of the development of atherosclerosis. 
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